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Since the initial cloning of fractalkine/CX3CL1, it was proposed that the only known member
of the CX3C or δ subfamily of chemotactic cytokines could play some significant role in
the nervous system, due to its high expression on neurons. The pivotal description of the
localization of the unique CX3CL1 receptor, CX3CR1, on microglial cells, firmed up by the
generation of cx3cr1GFP/GFP mice, opened the road to the hypothesis of some specific
key interactions between microglia and neurons mediated by this pair. This expectation
has been indeed supported by recent exciting evidence indicating that CX3CL1-mediated
microglia-neuron interaction modulates basic physiological activities during development,
adulthood and aging, including: synaptic pruning; promoting survival of neurons and
neural precursors; modulating synaptic transmission and plasticity; enhancing synapse
and network maturation; and facilitating the establishment of neuropathic pain circuits.
Beyond playing such fascinating roles in physiological conditions, CX3CL1 signaling has
been implicated in different neuropathologies. Early papers demonstrated that the levels
of CX3CL1 may be modulated by various toxic stimuli in vitro and that CX3CL1 signaling
is positively or negatively regulated in EAE and MS, in HIV infection and LPS challenge, in
epilepsy, in brain tumors, and in other neuropathologies. In this review we focus on the
experimental evidence of CX3CL1 involvement in neuroprotection and survey the common
molecular and cellular mechanisms described in different brain diseases.
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The CX3CL1/CX3CR1 axis, together with CD200/CD200R, have
mainly been studied in the context of their involvement in halt-
ing potentially toxic activated microglial phenotypes (Biber et al.,
2007). The phenotypes embodied by the term “microglia activa-
tion” have been hotly debated. Recent nomenclatures proposed
M1- and M2-like microglial phenotypes, characterized by the
production of pro- or anti-inflammatory cytokines and mark-
ers, named after the alternative activation states of macrophages
(Mantovani et al., 2005). The transition between these two forms,
however, is not all or none and several intermediate microglia phe-
notypes have been described, together with the identification of
overlapping features between alternatively activated phenotypes
(Ponomarev et al., 2007, 2013; Olah et al., 2012; Crain et al., 2013).
Furthermore, it’s now evident that no M1/M2 polarization can be
supported, even for peripheral macrophages (Xue et al., 2014).
Given contemporary approaches to genome wide expression
profiling, we now face the welcome prospect of devising a robust,
meaningful account of microglial reactive phenotypes.
In spite of this complex picture, there is a general consensus
on the relatively unique role of the CX3C system in mediating key
microglial activities, mainly because of its privileged position at the
interface with neurons. Microglia-neuron interaction is dynamic,
as revealed by in vivo video microscopy using cx3cr1GFP/+
mice and disclosing that microglia branches continuously sur-
vey neuronal surfaces and the cerebral microenvironment in the
healthy brain, presumably to sense dysfunctional synapses, dam-
aged neurons, or the presence of potentially dangerous agents
(Davalos et al., 2005; Nimmerjahn et al., 2005). Thus, in the adult
brain, microglia may exert a sentinel function for neurons and,
when neuronal damage occurs, microglia rapidly react to protect
or to eliminate neurons, if irreversibly damaged. CX3C signal-
ing is deeply involved in this rescue process, directly modulating
different aspects of microglia biology important for neuron pro-
tection, like the production of soluble factors directly involved
in neuron survival, the modulation of phagocytic activity, but
also indirectly affecting other cell types (resident or infiltrating)
present in brain parenchyma that, in turn, might influence neuron
survival.
CX3CR1 was localized to microglia and CX3CL1 to neurons
using in situ hybridization, by Harrison et al. (1998). Availability
of mice with a GFP fluorescent reporter for CX3CR1 transcrip-
tion confirmed the former finding in adult mice (Cardona et al.,
2006) and subsequent studies showed that CX3CR1 is charac-
teristic of microglia throughout embryogenesis and during the
murine lifespan (Ginhoux et al., 2010; Mizutani et al., 2012; Schulz
et al., 2012). Subsequently, Kim et al. (2011) developed a CX3CL1
reporter and showed a similar neuronal distribution of CX3CL1
in all regions of the adult brain. These expression patterns are
somewhat modulated but do not fundamentally alter in disease
models. Therefore, CX3CL1/CX3CR1 signaling provides insight
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into microglial–neuronal interactions throughout the lifespan
(Table 1) and in an immense variety of pathological conditions.
This review summarizes a portion of this research.
NEUROTOXICITY MODULATION: CYTOKINE AND GROWTH
FACTOR PRODUCTION
The CX3CL1/CX3CR1 signaling participates in the control of pro-
duction and release of several cytokines from microglia. Earlier in
vitro studies demonstrated that LPS- and IFNγ-induced release of
cytokines such as interleukin-1β (IL-1β), TNFα, 8-isoprostane,
NO, and IL-6 in cultured microglia was efficiently blocked by
CX3CL1 stimulation (Zujovic et al., 2000, 2001; Mizuno et al.,
2003). Since then several papers confirmed and provided further
in vivo evidence supporting the hypothesis that, together with
other molecules like CD200, CD22 and CD172, CX3CL1 signaling
in the brain reduces microglia reactivity to toxic stimuli, main-
taining microglia in a modulated state (Biber et al., 2007). This
hypothesis can be evaluated even though the status of “microglial
activation” is profoundly uncertain [see (Biber et al., 2014) for a
recent review].
MODULATION OF IL-1β SIGNALING
Interleukin-1β is an inflammatory cytokine playing pivotal roles
in local and systemic processes and is a key inducer of peripheral
and central immune responses to infection or injury. Inhibition
of IL-1β signaling has beneficial effects in a variety of experi-
mental paradigms of acute brain damage. Despite controversial
data on its neurotoxic effects in vivo and in vitro, IL-1β is consid-
ered a promising clinical target in several neuropathologies (Allan
et al., 2005). In paradigms of brain injury where IL-1β increases,
CX3CL1 reduces IL-1β levels, correlating with protection from
damage.
Increased production of IL-1β by microglial cells isolated from
the brain of Cx3cr1−/− mice upon systemic LPS challenge was
described by Cardona et al. (2006). Cx3cr1−/− microglial cells
from LPS-challenged mice provided a toxic insult when trans-
planted in the forebrain of wild type mice, resulting in neuronal
TUNEL labeling. Interestingly these toxic effects were prevented
eliminating IL1R signaling either with IL-1 receptor antagonist a
(IL-1Ra) or in IL1−/− mice.
Cardona et al. (2006) also showed enhanced dopaminergic cell
loss in Cx3cr1−/− or Cx3cl1−/− mice after peripheral MPTP
administration. Morganti et al. (2012) asked two follow-on ques-
tions: what was the role of cytokine production? and which
CX3CL1 isoform (soluble or membrane-associated) was respon-
sible for the neuroprotective effect? They reported that IL-1β
signaling was blunted by soluble AAV-CX3CL1, injected in the
substantia nigra pars compacts of MPTP-injected cx3cl1−/− mice,
so that less IL-1β and TNFα were produced in the ventral mes-
encephalon and microglial CD68 expression was reduced. These
alterations in cytokine profile induced by soluble AAV-CX3CL1
correlated with reduced death of dopaminergic TH positive neu-
rons and improved motor coordination on accelerating rotarod. A
protective effect of soluble CX3CL1 on dopaminergic neurons was
demonstrated by the same authors in a rat model of PD, induced
by intrastriatal 6-OHDA injection (Pabon et al., 2011).
CX3CL1 decreased in the brain of aged mice possibly due
to neuronal loss, and this change is accompanied by an altered
effector state of microglia (Lyons et al., 2009; Wynne et al., 2010;
Bachstetter et al., 2011). In aged mice, the response to systemic
infection is amplified by the microglia effector response: LPS
administration evokes an increased IL-1β and a reduced TGFβ
expression, in comparison with young adult animals (Wynne et al.,
2010).
Table 1 | Documented effects in (ex) vivo of CX3CL1/CX3CR1 signaling in lifespan.
Period Effects Mechanisms Reference
Embryo Active in early microglial precursors Unknown Mizutani et al. (2012)
Postnatal Circuitry refinement
Cortical neuron survival
Glutamatergic synapse maturation
Synaptic engulfment; timing of microglia
recruitment
IGF-1 production
Delayed microglia-synapse interaction
during development
Paolicelli et al. (2011),
Hoshiko et al. (2012),
Zhan et al. (2014)
Ueno et al. (2013)
Arnoux et al. (2013)
Adult Dentate gyrus neurogenesis
Modulation of inflammatory cytokine
production
IL-1β modulation
Unknown
Rogers et al. (2011), Maggi et al. (2011),
Cardona et al. (2006)
Modulation of glutamatergic
neurotransmission
Post-synaptic (GluR1 dephosphorylation;
NMDAR potentiation through D-Ser)
modulation
Ragozzino et al. (2006),
Bertollini et al. (2006),
Maggi et al. (2009), Scianni et al. (2013)
Progenitor cell proliferation in the
olfactory bulb
Inflammatory cytokine production and
monocyte recruitment
Blomster et al. (2011)
Aging Dentate gyrus neurogenesis
Microglia effector state
IL-1β modulation
PI-3K
Bachstetter et al. (2011)
Lyons et al. (2009), Wynne et al. (2010),
Bachstetter et al. (2011)
Frontiers in Cellular Neuroscience www.frontiersin.org August 2014 | Volume 8 | Article 229 | 2
Limatola and Ransohoff Mechanisms of CX3C signaling
Aging is reported to decrease neurogenesis in the hippocam-
pal region of the brain (Kuhn et al., 1996). Similarly to aging,
deficits in CX3CL1 signaling due to gene deletion or caused by
CX3CR1 blocking antibodies reduced the number of progenitor
cells in the hippocampal dentate gyrus (Bachstetter et al., 2011;
Maggi et al., 2011). CX3CL1 administration reverted the age-
related decrease in neurogenesis and chronic blockade of CX3CR1
function reduced neurogenesis and increased IL-1β in young adult
mice (Bachstetter et al., 2011). IL-1β was implicated in the reduced
survival and proliferation rate of neuronal progenitors in the
hippocampal region of CX3CR1−/− mice, since IL-1Ra reverted
the observed phenotypes (Bachstetter et al., 2011; Rogers et al.,
2011).
The involvement of IL-1 in CX3CL1-induced effects in exper-
imental models of AD is suggested by several lines of evi-
dence. Mouse deleted of cx3cr1 showed a strong increase of
microtubule-associated protein tau (MAPT) phosphorylation
upon LPS challenge, and humanized MAPT transgenic mice
crossed with cx3cr1−/− mice exhibited accelerated behavioral
impairment along with increased MAPT hyperphosphorylation
and aggregation. These data, together with the observation
that microglia-induced MAPT phosphorylation in neurons can
be blocked by IL-1Ra and p38 inhibitors further supports the
hypothesis that inhibiting production of IL-1β constitutes a cen-
tral mechanism for CX3CL1 neuroprotective signaling (Bhaskar
et al., 2010). Additional possible targets of CX3CL1 signaling in
AD have been suggested: Cho et al. (2011) demonstrated that
hAPP/cx3cr1−/− mice have exacerbated neuronal and cognitive
function defects and increased inflammatory responses in com-
parison with hAPP/cx3cr1+/+ mice. The lack of cx3cr1 in this
AD mouse model (hAPP-J20) did not modify plaque deposi-
tion but increased tau phosphorylation, cognitive deficits, and
microglia activation, along with enhanced IL-6 and TNF-α lev-
els. In line with these observations, AD autopsy brain sections
showed reduced CX3CL1 levels in the cortex and hippocampus
regions. Further supporting a potential role for CX3CR1 sig-
naling in AD pathogenesis, Lee et al. (2010) reported that in
two different mouse models of AD (APPS1 and R1.40), char-
acterized by different velocity of β-amyloid deposition, crossing
with cx3cr1−/− mice reduced the extent of amyloid deposi-
tion, the number of dystrophic neurons and of plaque-associated
microglia cells. This protected phenotype was accompanied by
increased CCL2 and TNF-α and elevated IL-1β expression. By
contrast, a potentially toxic effect for CX3CL1 was suggested
by Wu et al. (2013) demonstrating that the deficits induced
by β-amyloid injection in hippocampal CA1, as well as the
increased IL-1β expression and microglia activation, were all
reverted by central CX3CR1 suppression by siRNA delivery.
A toxic effect for CX3CR1 signaling in AD was also pro-
posed by Fuhrmann et al. (2010) that found a reduced neuronal
loss when the 3xTg AD mice were crossed with cx3cr1−/−
mice. In summary, CX3CR1/CX3CL1 signaling modifies AD-
related pathology quite consistently but a unified concept of
the net outcome of the effects has not been conclusively
proven.
Alteration of IL-1β levels was reported in cx3cr1-deficient mice
upon focal cerebral ischemia. Dénes et al. (2008) demonstrated
a reduction in IL-1β and TNF-α production in brains of
cx3cr1−/− mice upon induction of cerebral ischemia, together
with reduced ischemic volume and less neuronal cell death.
Similar experiments in a focal brain ischemia model were
performed by Soriano et al. (2002) in cx3cl1 deficient mouse
and confirmed lower ischemic volume in the absence of
CX3CL1/CX3CR1 signaling. This result was later confirmed
in a pMCAO model (Cipriani et al., 2011). In apparent con-
trast, when CX3CL1 was exogenously administrated to wt mice
and followed by pMCAO, a significant reduction of ischemic
volume was observed while in cx3cl1−/− mice CX3CL1 adminis-
tration worsened the effects of ischemia (Cipriani et al., 2011).The
mechanisms underlying divergent effects of CX3CL1 admin-
istration to wt and Cx3cl1−/− mice remain uncertain. In
favor of a protective effect of CX3CL1 in cerebral ischemia,
Donohue et al. (2012) reported that stroke patients exhib-
ited a positive correlation between high plasma CX3CL1 lev-
els and a better clinical outcome. Interestingly, Pimentel-
Coelho et al. (2013) demonstrated a protective role for CX3CR1
in neonatal hypoxic ischemia in female mice, with a pos-
sible gender specific protective effect. The authors demon-
strated that hippocampal CX3CL1 was reduced by ischemia
and that Cx3cr1−/− mice showed worse learning deficits and
hippocampal damage after ischemia (Pimentel-Coelho et al.,
2013).
In an in vitro genetic model of amyotrophic lateral sclerosis
(ALS), where the mutated SOD1G93A is specifically expressed by
astrocytes, Sun et al. (2013) reported that conditioned medium
from mesenchymal stem cell (MSC) cultures increased CX3CL1
and reduced TNFα, IL6, and iNOS expression on astrocytes, and
mediated a protective effect towards primary motor neurons. In
vivo, MSC administration improved the functional outcome of
mutated mice. In cultured microglia, the presence of mutated
SOD1G93A also increased CX3CR1 levels.
Taken together, these data demonstrate that CX3CL1 atten-
uates inflammatory cytokine production, strongly modulating
the neuroprotective activity of microglia in several brain dis-
eases.
PERMISSIVE EFFECTS OF ADENOSINE
Adenosine is a well-established modulator of synaptic transmis-
sion and has protective effects in the nervous system, primarily
mediated through adenosine type 1 receptor (A1R). Adenosine
is released by neurons and glial cells and its level in the brain is
regulated essentially by the activity of adenosine kinase (ADK),
and 5′ nucleotidase acting on extracellular ATP (Boison et al.,
2010).
Upon CX3CL1 treatment of cultured microglia, increased
extracellular adenosine release is observed (Lauro et al., 2008,
2010). In in vitro models of excitotoxicity (Lauro et al., 2010) and
in vivo models of cerebral ischemia, the neuroprotective activity of
CX3CL1 requires A1R activation (Cipriani et al., 2011). This neu-
roprotective mechanism does not derive from a direct microglia-
neuron cross talk, requiring (at least in vitro) the involvement of
astrocytes whose A1Rs are stimulated by adenosine released from
microglia, increasing astrocyte glutamate transporter (GLT-1)
expression and activity (Catalano et al., 2013).
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The neuroprotective activity of adenosine has been correlated
to its ability to hamper the release of excitatory glutamate at pre-
synaptic terminals (Fredholm et al., 1983). In this regard, it is
interesting to note that CX3CL1 has a wide spectrum of modu-
latory activities on glutamatergic neurotransmission, interfering
with: (i) pre-synaptic glutamate release, (ii) the amplitude of
AMPA currents, thereby altering GluR1 phosphorylation state
(post-synaptic modulation), (iii) LTP expression and LTD induc-
tion in hippocampal CA1 region, (iv) synaptic NMDAR currents
through D-serine release from glia (Meucci et al., 2000; Limatola
et al., 2005; Bertollini et al., 2006; Ragozzino et al., 2006; Maggi
et al., 2009; Scianni et al., 2013); (v) glutamatergic synapse mat-
uration during development (Paolicelli et al., 2011; Arnoux et al.,
2013).
All together these data demonstrate that excitatory neuro-
transmission, which is deeply implicated in the most common
neurotoxic pathways, is affected by CX3CL1/CX3CR1 signaling,
with permissive cooperativity of the adenosine system.
GROWTH FACTORS PRODUCTION
Microglia produce a number of growth factors providing trophic
support to developing or damaged brain circuits. During brain
development, in the first postnatal week, CX3CR1 expression on
microglia is important for the survival of cortical neurons of layer
V, by regulating the production of insulin-like growth factor-1
(IGF-1; Ueno et al., 2013). In particular, increased death of layer V
neurons was observed in the cerebral cortex of cx3cr1GFP/GFP mice,
in which microglia produced a significantly reduced amount of
the growth factor IGF-1. So during brain development, CX3CR1-
mediated IGF-1 secretion from microglia modulates neuronal
survival in postnatal cortical layer V.
A specific BDNF polymorphism (Val66Met) is associated with
memory deficits and increased vulnerability to anxiety and depres-
sive disorders both in humans and mice. Interestingly, this
polymorphism also associates with impaired CX3CL1/CX3CR1
hippocampal signaling, reducing expression of CX3CL1 protein
and mRNA in dorsal hippocampus (Wang et al., 2014). Chronic
CX3CL1 infusion in the hippocampal region of Val66Met mice
recovered memory deficits, restored neurogenesis in the DG and
increased Akt phosphorylation levels.
NEUROTOXICITY MODULATION: MICROGLIA PHAGOCYTIC
ACTIVITY
One of the most intriguing functions of microglia in the
central nervous system is certainly its activity as the resi-
dent phagocyte. In development and in pathological neuroin-
flammatory conditions, microglial phagocytosis is important
for the elimination of dead and damaged neurons, myelin
residues and β-amyloid peptides [reviewed in (Sierra et al.,
2013)]. During normal brain development, microglial phago-
cytosis is involved in eliminating supernumerary neurons, but
also in synaptic pruning and circuit refinement (Sierra et al.,
2010; Tremblay et al., 2010). Among the key factors that
emerged as potential modulators of neuron phagocytosis by
microglia during development is the complement system, with
the proteins C1q and C3 expressed on synapses and microglial
CR3/CD11b mediating the elimination of immature and weakly
active synapses (Schafer et al., 2012). TGF-β produced by
astrocytes signals to retinal ganglion cells for C1q expression
(Bialas and Stevens, 2013), thus favoring retinogeniculate refin-
ing, and inserting astrocytes in microglia-neuron communica-
tion.
Cell damage causes high-grade ATP release (both from dam-
aged cells and through astrocyte exocytosis) regulating microglial
process extension (Davalos et al., 2005) and also contributing
to inflammasome activation within microglia (Ransohoff and
Brown,2012). Under stress, neurons manifest the phosphatidylser-
ine (PS) “eat me” signal which can be recognized by several
microglia receptor/adaptor complexes including Gas6/MerTK and
MFGE8/vitronectin receptor (De Simone et al., 2004; Elliott et al.,
2009). In ischemic conditions potentially viable neurons reversibly
express PS on their surface and are vulnerable to be taken
up and destroyed by microglia (Neher et al., 2011). Selective
elimination of MFGE8/vitronectin receptor “eat me” signaling
strongly improved experimental stroke outcome (Neher et al.,
2013).
CX3CR1 signaling also modulates microglia phagocytosis of
neurons and their processes in both physiological and pathologi-
cal conditions. During development, CX3CL1/CX3CR1 signaling
contributes to refinement of synaptic elements in varied CNS
regions during the postnatal “critical period” (Tremblay et al.,
2010; Paolicelli et al., 2011; Hoshiko et al., 2012). This fine-tuning
of anatomical connections is important to establish and build an
optimal functional circuitry (Zhan et al., 2014).
In Alzheimer’s disease (AD), CX3CL1/CX3CR1 blockade mod-
ulates microglia phagocytic activity in a way that markedly
attenuates amyloid deposition (Lee et al., 2010; Liu et al., 2010).
In particular, CX3CR1 deficient microglia show increased phago-
cytic activity when crossed with different AD mouse models
CRND8 (Liu et al., 2010) or APPPS1 and R1.40 (Lee et al.,
2010), resulting in attenuated Aβ deposition. Based on results
that look beyond amyloid deposition in various models, the
overall outcome of eliminating CX3CR1 signaling remains in
doubt (Bhaskar et al., 2010; Fuhrmann et al., 2010; Cho et al.,
2011).
Neurons damaged by toxic insults, like glutamate, release
more CX3CL1 that increases MFG-E8 expression on microglia
(Leonardi-Essmann et al., 2005; Fuller and Van Eldik, 2008; Noda
et al., 2011). As noted above, MFG-E8 is a PS receptor that
recognize PS on injured neurons and acts as an adaptor recog-
nized by microglial vitronectin receptor, inducing damaged-cell
uptake. CX3CL1 up-regulation of MFG-E8 expression was asso-
ciated to increased heme oxygenase 1 (HO-1) expression through
the MAPKs ERK and JNK and the nuclear factor erythroid 2
related factor (NFE2LE). Lastres-Becker et al. (2014) reported
that CX3CL1 reduced Tau-induced microgliosis via up-regulating
transcription factor NRF2/NFE2LE, along with increased HO-1
expression. Since the increased expression of HO-1 is reported
to mediate anti inflammatory activities (Chora et al., 2007),
this pathway could be involved in the reported neuroprotective
effects of CX3CL1 in different Tau pathology models (Nash et al.,
2013).
These data indicate that the clearance and phagocytic activ-
ity of microglia can be modulated by CX3CL1 signaling through
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varied mechanisms, and that the final outcome in term of neu-
roprotection or neurotoxicity might result from the presence
of co-stimulatory signals and, consequently, from the effector
programs of microglia.
NEUROTOXICITY MODULATION: EFFECTS ON NEURAL
PRECURSORS
In vitro, CX3CL1 promoted survival of neural precursor cells
upon growth factor withdrawal from the culture medium (Krath-
wohl and Kaiser, 2004). Further, cx3cr1−/− mice have reduced
neurogenesis in the hippocampal DG region (Bachstetter et al.,
2011; Maggi et al., 2011) but this reduction was accompanied
by contrasting effects on memory deficits and synaptic plastic-
ity: Maggi et al., (Maggi et al., 2011) reported that cx3cr1−/−
mice had increased hippocampal LTP and performed better in the
Morris water maze test, while, in the same mouse strain, Rogers
et al. (2011) described reduced hippocampal LTP and deficits in
the Morris water maze. At least in part, these conflicting data
reflect the lack of simple relations between DG neurogenesis,
plasticity processes in the hippocampal CA1 region and learning
behavior.
More recently, Vukovic et al. (2012) demonstrated that
CX3CR1 deficiency impairs neurogenesis both in young and aged
mice and that voluntary physical exercise increased brain CX3CL1
levels and DG neurogenesis, both effects being abolished by
intrahippocampal CX3CR1 antibody injection.
In the olfactory bulb, CX3CR1 deletion increased olfactory
sensory neuron death upon bulbectomy and cx3cr1−/− mice
showed reduced proliferation of intraepithelial stem progen-
itor cells, increased macrophage recruitment in the lesioned
epithelium and increased TNF-α and IL-6 levels (Blomster et al.,
2011).
All together these data suggest that neuroprotective effects of
CX3CL1 might arise partly from an increased proliferation or
survival of progenitor elements in selected brain regions where
neurogenesis continues throughout adult life.
NEUROTOXICITY MODULATION: INDIRECT EFFECTS
MODULATION OF ASTROCYTE ACTIVITY
In the CNS, the unique expression of CX3CR1 on microglia
clearly suggests that the neuroprotective effects of CX3CL1 depend
primarily on the direct communication between microglia and
neurons. Recent evidence suggested that CX3CL1/CX3CR1 sig-
naling in neuroprotection again excitotoxic insult might not be
restricted to a direct microglia-neuron communication but also
involves indirectly modulation of astrocyte activity. Catalano et al.
(2013), in fact, demonstrated that CX3CL1, acting on microglia,
induced the production and release of soluble factors that exerted
their effects on astrocytes, inducing the functional up regulation
and the increased expression of the excitatory amino acid trans-
porter GLT-1. As already reported in in vitro and in vivo systems
(Lauro et al., 2010; Cipriani et al., 2011), this cross-talk requires the
“permissive” presence of adenosine, specifically acting on astro-
cyte A1R (Catalano et al., 2013). These data demonstrated for the
first time a role for astrocytes in mediating the neuroprotection
induced by CX3CL1/CX3CR1 signaling between microglia and
neurons.
EFFECTS THROUGH LEUKOCYTE RECRUITMENT
Neuroprotective effects of CX3CL1 could also arise from
hematogenous leukocytes that enter the brain upon specific,
injury-induced challenge.
In mouse experimental allergic encephalomyelitis (EAE)
Huang et al. (2006) demonstrated that CX3CR1 deficient mice
had an exacerbated phenotype, with severe spastic paralysis and
hemorrhagic inflammation in the CNS, resulting in higher mor-
tality. The increased toxicity resulted from an altered control of NK
cells entry into the brain of EAE-affected animals. These findings
were extended by Garcia et al. (2013), who showed that CX3CR1
deficiency limited to bone marrow cells of mice with EAE resulted
in more severe pathology, with increased demyelination, axonal
damage and reduced calbindin positive neurons in the cerebellum.
These effects correlated with increased CD115+, Ly6ClowCD11c+
dendritic cell infiltration in the CNS and increased IL-17 and IFNγ
expression in the cerebellum, forebrain and spinal cord.
Mills et al. (2008) reported that in CD73−/− mice, where the
ectonucleotidase responsible for extracellular adenosine accumu-
lation was absent, EAE induction produced a milder phenotype.
More recently, the same group (Mills et al., 2012) reported that
extracellular adenosine increased CX3CL1 expression and that
CX3CL1 promoted lymphocyte entry into the brain of EAE mice.
Therefore, in CD73 deficient mice, extracellular adenosine cannot
be produced, CX3CL1 is not upregulated and a reduced amount of
lymphocytes enter cerebral parenchyma, resulting in a protected
phenotype (Mills et al., 2012).
In focal cerebral ischemia, Dénes et al. (2008) reported a
reduced leukocyte (CD45+ cells) infiltration in the brain of
cx3cr1−/− mice and a consistently reduced damaging of the blood
brain barrier. This correlated with a protected phenotype, with
reduced ischemic volume and lesser numbers of apoptotic cells
and a better performance in the behavioral test of adhesive tape
removal.
All together these data highlight that CX3CL1/CX3CR1 sig-
naling modulates the entry of hematogenous leukocytes, with
beneficial or deleterious consequences contingent on context.
CONCLUSION
This review highlights the manifold effects of altering
CX3CR1/CX3CL1 signaling, which can be observed throughout
the lifespan from early embryogenesis through diseases of the
aging brain. For the most part, CX3CR1/CX3CL1 can be viewed
as a fulcrum with which to modify microglial physiology to probe
into the panoply of functions of these versatile and essential cells.
Adding to complexity but also lending heuristic value, the effects
of modifying CX3CR1/CX3CL1 pathways are extremely context
dependent. Nevertheless in each case insights about upstream and
downstream signaling from CX3CR1/CX3CL1 have been informa-
tive and may point to new therapeutic directions for brain disease.
Finally, it is now clear that macroglia (such as astrocytes) and
hematogenous leukocytes also contribute to the varied physiology
of the CX3CR1/CX3CL1 signaling system.
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